Brian Park, PharmD

Kineret is an interleukin-1 receptor antagonist.

The designation is supported by data from the 12-week, randomized, double-blind phase 2 FILLMORE trial.

The 2022 CDC Clinical Practice Guideline is intended to help clinicians weigh the benefits and risks of opioids and alternative pain treatments for outpatients.

Findings showed that the booster dose elicited robust antibody responses comparable to, or exceeding levels associated with the efficacy data in the primary series of the vaccine.

SKOUT is designed to recognize suspicious tissue and provide real-time feedback to gastroenterologists.

Aponvie is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant as a 30-second IV injection.

RoxyBond is an abuse-deterrent formulation of immediate-release oxycodone that features a unique abuse-deterrent technology.

The approval was based on data from a phase 3 trial which included 2260 participants 12 to 15 years of age enrolled in the United States.

Patients prescribed the 30mg dose who receive the 60mg dose may potentially be at risk for overdose and death.

The totality of the evidence led the FDA to determine that the criteria for issuing an EUA had not been met.